Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SHV-type beta-lactamases.

L S Tzouvelekis1, R A Bonomo

  • 1Laboratory of Antimicrobial Agents, Department of Microbiology, Medical School, National University of Athens, Greece. Ltzouvel@cc.uoa.gr

Current Pharmaceutical Design
|December 14, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Escherichia coli</i> producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen.

JAC-antimicrobial resistance·2025
Same author

Exploring avibactam and relebactam inhibition of <i>Klebsiella pneumoniae</i> carbapenemase D179N variant: role of the Ω loop-held deacylation water.

Antimicrobial agents and chemotherapy·2023
Same author

Acinetobacter quorum sensing contributes to inflammation-induced inhibition of orthopaedic implant osseointegration.

European cells & materials·2022
Same author

Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.

Antimicrobial agents and chemotherapy·2022
Same author

Detection in two hospitals of transferable ceftazidime-avibactam resistance in <i>Klebsiella pneumoniae</i> due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2020
Same author

Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same journal

Fentanyl and its Analogs: A Medicinal Chemistry Perspective on Therapeutic Potential and Abuse Liability.

Current pharmaceutical design·2026
Same journal

Acne Vulgaris: Integrating Pathophysiology with Conventional, Herbal, and Nanocarrier-Based Therapeutic Strategies.

Current pharmaceutical design·2026
Same journal

Systems Pharmacology and Pharmaco-Transcriptomic Insights into Bauhinia variegata for Polycystic Ovary Syndrome Management.

Current pharmaceutical design·2026
Same journal

Curcumin and Cognitive Health: Insights from Randomized Controlled Trials.

Current pharmaceutical design·2026
Same journal

Inorganic Materials-integrated Porphyrin for Drug Delivery in Cancer Therapy: Promises, Challenges and Outlooks.

Current pharmaceutical design·2026
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
See all related articles

SHV beta-lactamases, including variants with extended-spectrum activity, are prevalent among enterobacteria. Understanding their evolution and spread is crucial for developing new antibiotics and effective treatment strategies.

Area of Science:

  • Microbiology
  • Biochemistry
  • Molecular Biology

Background:

  • Plasmid-mediated SHV beta-lactamases, including SHV-1 and numerous variants, exhibit extended-spectrum activity against broad-spectrum cephalosporins.
  • These enzymes, originating from Klebsiella pneumoniae chromosomal penicillinase, belong to molecular class A serine beta-lactamases, similar to TEM enzymes.

Purpose of the Study:

  • To elucidate the structural and functional characteristics of SHV beta-lactamases.
  • To understand the evolutionary trajectory, substrate hydrolysis, and dissemination mechanisms of SHV beta-lactamases.
  • To inform the development of novel antimicrobial agents and antibiotic policies.

Main Methods:

  • Comparative structural analysis of SHV-1 and TEM-1 beta-lactamases.
  • Investigation of substrate hydrolysis profiles for various SHV variants.

Related Experiment Videos

  • Tracking the spread of SHV beta-lactamases via plasmid analysis.

    • Main Results:

    • SHV-1 possesses a wider active site than TEM-1, leading to distinct residue positioning.
    • Extended-spectrum (ES) SHV beta-lactamases are the most prevalent ES enzymes, conferring resistance to advanced cephalosporins and monobactams.
    • Mutations in ES SHV enzymes broaden their spectrum to oximino-beta-lactams but reduce activity against penicillins and increase susceptibility to inhibitors.

    Conclusions:

    • SHV beta-lactamases are significant contributors to antibiotic resistance in enterobacteria.
    • Understanding SHV enzyme evolution and spread is vital for combating antimicrobial resistance.
    • Targeted strategies against SHV beta-lactamases are needed for effective treatment of bacterial infections.